Fig 1. Overall Survival With Docetaxel According to Previous Paclitaxel Treatment Status.

Fig 1. Lymphatic drainage of blank hydrogel particles.

Figure 2. Examples of Dermoscopic Images Captured by Patients Using the Mobile Dermatoscope

Fig. 1. Tumor response to voluntary aerobic exercise.

Fig 3. Duration of response in patients who achieved objective response by dose treatment arm. Based on data cutoff date of March 5, 2014.

FIGURE 1. Comparison of SUVmax for DTC patients harboring BRAFV600E mutation versus BRAF-WT. *P = 0.019.

Figure 1. scMHF interacts with Mph1 and Smc5 in vivo and in vitro.

Fig 1. The material used for transparency tracing of melanocytic nevi is simple to obtain and of negligible cost: A translucent flexible film (3M) (support for image records) and a fine permanent ink pen for transparencies (Stabilo F, 0.4 mm width) for tracing contours; this material is showed herein for drawing the border of an intermediate melanocytic nevus located on the back of a child.

Fig 1. CONSORT diagram. Patients who received none of the protocol therapy were excluded from the assessment of toxicity.

FIGURE 1. Structure of 90Y-DOTA-AR

Fig 1. Kaplan-Meier estimates of disease-free survival for patients with locally advanced primary T4 and locally recurrent colorectal cancer.

Graphical Abstract

Fig 1. Mechanisms of Stem Cell-Based Brain Repair.

Fig 1. Target antigens for RIT.

Fig 1. Targeted expression of eGFP-KRASmutant transgene in zebrafish pancreas.

Fig 1. Efficacy of novel agents in relapsed, refractory mantle cell lymphoma. Single-agent overall response rates (CR + PR) are shown.

Fig 1. Representative radiation plans for (A) a rectal cancer patient treated with 3-dimensional conformal radiation therapy and (B) an anal cancer patient treated with IMRT.

Fig 2. Pale areas in gastric mucosa of a patient with a germline CDH1 mutation harbouring signet ring cell focus during white light endoscopy.

Fig 1. Graph shows ROC analysis for global T4 determination by three readers with histopathology as reference standard.

Figure 1A. In 9 patients demonstrating complete single-unit dominance from 28 days after CBT, the unit responsible for sustained donor hematopoiesis is indicated in green whereas nonengrafting units are shown in red. Only 1 patient with complete unit dominance demonstrated TL maintenance after transplantation with a mean percentage TL gain of 11.5% (indicated with the asterisk).

Fig 1. CRISPR/Cas-Mediated Targeting of the OCT4 Locus through Drug Selection.

Fig 1. Effect of Sirs on Transcription of a1.